About Frontmed Trading Ltd.
Frontmed is a privately owned medical device distributor with over 25-years experience in the UK Health Sector. Frontmed delivers rapid market access for newly commercialized technologies.
Specialists in strategy development, brand management, sales & marketing, of technologies that represent a dynamic evolution to the status quo (disruptive technologies).
"Aura fits our portfolio perfectly. In Great Britain, many thousands of unnecessary biopsies are performed every year due to inadequate diagnosing capability. Aura, represents a new opportunity to reduce unnecessary biopsies, as well as improve the confidence to biopsy lesions that ought to be. Potential savings to Healthcare providers are enormous" - Daniel Krelle.
For more information on Frontmed, and our trusted partners, visit the Company's website at http://www.frontmed.org
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura for skin cancer detection and the Verisante Core series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura has been approved for sale in Canada, Europe and Australia. The Core has not yet been approved for sale.
Verisante Aura was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Verisante Technology, Inc.
President & CEO
Most Popular Stories
- Slow Week Ahead of December FOMC Meeting
- Hispanics Seek to Grow School Board Members
- GM Bailout Saved 1.2 Million U.S. Jobs, Report Says
- Bitcoin Used to Buy Tesla Car
- U.S. Companies Eager for Iranian Business
- 'Knockout Game': Myth or Menace?
- Banks Fret as Volcker Vote Approaches
- Questions Remain in Jenni Rivera's Death
- Yellen Set to Become One of World's Most Powerful Women
- Paul Walker Fans Pay Respects